Original Article
Relation of an Interleukin-10 Promoter Polymorphism to Graft-versus-Host Disease and Survival after Hematopoietic-Cell Transplantation
N Engl J Med 2003; 349:2201-2210December 4, 2003
- Abstract
Background
Polymorphisms in cytokine genes can influence immune responses, inflammation, and tissue injury and may affect the outcome of hematopoietic stem-cell transplantation.
Methods
We analyzed single-nucleotide polymorphisms in the genes for interleukin-1β, interleukin-1–receptor antagonist, interleukin-6, interleukin-10 (IL10), and tumor necrosis factor α in 570 transplant recipients and their HLA-identical sibling donors. Genotypes were tested for an association with graft-versus-host disease (GVHD) by multivariable analysis. A second cohort of 423 transplant recipients was independently analyzed for the genotype associations identified in the first cohort.
Results
The recipient's IL10 promoter region genotype was significantly associated with the risk of acute GVHD in the first cohort. Analysis of all 993 transplant recipients showed that, as compared with the C/C genotype, the IL10 –592A/A genotype was associated with a decreased risk of grade III or IV acute GVHD (hazard ratio, 0.4; 95 percent confidence interval, 0.2 to 0.9; P=0.02) and death in remission (hazard ratio, 0.6; 95 percent confidence interval, 0.3 to 1.0; P=0.05). A haplotype analysis showed that the IL10 –592A allele was a specific marker for a promoter haplotype, T-C-A-T-A, defined by five polymorphisms at positions –3575, –2763, –1082, –819, and –592, respectively.
Conclusions
Among recipients of hematopoietic cells from an HLA-identical sibling, the IL10 –592A allele is a marker of a favorable outcome after transplantation.
Media in This Article
Figure 1
Cumulative Incidence of Grade III or IV Acute Graft-versus-Host Disease (GVHD) (Panel A) and Death in Remission (Panel B), According to the Interleukin-10 Genotype at Position –592 among Transplant Recipients.Figure 2
A Map of the Interleukin-10 Gene and 5' Upstream Promoter Region (Panel A) and the Six Five-Locus Interleukin-10 Promoter-Region Haplotypes Identified in the Combined Cohort of 993 Patients and Their Estimated Frequencies (Panel B).Article Activity
- Article
Hematopoietic stem-cell transplantation can be lifesaving for patients with otherwise fatal diseases. However, mature T cells in the graft can initiate immune reactions that cause graft-versus-host disease (GVHD), a potentially fatal complication.1 Matching of donor and recipient for HLA2 and minor histocompatibility antigens3 is important to optimize the outcome of transplantation, because mismatches increase the risk of GVHD. Certain genes may also affect the outcome by modulating the intensity of inflammation and tissue injury associated with the alloimmune reaction and other transplantation-related complications.
Cytokines and other regulators of the immune response may have an important role in the pathogenesis of GVHD.4 Nucleotide variations in the genes encoding these molecules may affect the transcription or translation of the genes or the secretion or function of the corresponding proteins.5 We analyzed seven single-nucleotide polymorphisms located in five cytokine genes — interleukin-1 beta (IL1B), interleukin-1–receptor antagonist (IL1RA), interleukin-6 (IL6), interleukin-10 (IL10), and tumor necrosis factor α (TNFA) — in a group of 570 HLA-identical donor–recipient sibling pairs designated cohort 1. These polymorphisms correlate with gene function and susceptibility to disease.5 A statistically significant finding in this cohort led to independent testing in a second cohort. Results of a combined analysis demonstrated a significant association between polymorphisms in the promoter region of the recipient's IL10 gene and the risk of acute GVHD and death.
Methods
Patients
The entire study population consisted of 993 transplant recipients and their HLA-identical sibling donors. All patients received grafts containing T cells. The HLA genotypic identity of each recipient and donor was established as previously described.6 Inclusion criteria were the availability of pretransplantation blood samples, the use of methotrexate and cyclosporine for prophylaxis against GVHD, and the availability of acute GVHD grading scores before the study began. The study was divided into two phases and involved separate cohorts. The initial cohort consisted of 570 HLA-A2–positive donor–recipient pairs previously assembled for a different study.7 We used this cohort to screen for an association between GVHD and seven single-nucleotide polymorphisms in five cytokine genes. The second cohort included 423 recipients, most of whom were HLA-A2–negative. This cohort was used for confirmatory analysis. There were significant differences between these groups in the patients' ages, years of transplantation, and use or nonuse of total-body irradiation (Table 1Table 1
Characteristics of the Transplant Recipients in the First and Second Cohorts.). A final analysis of clinical end points included both cohorts. All recipients and donors gave written informed consent according to protocols approved by the institutional review board of the Fred Hutchinson Cancer Research Center.Nomenclature of Single-Nucleotide Polymorphisms
Seven single-nucleotide polymorphisms were studied in five genes: IL1B, IL1RA, IL6, IL10, and TNFA. Six of these single-nucleotide polymorphisms — –511C or T of IL1B, +3954C or T of IL1B, –174C or G of IL6, –592A or C of IL10, –1082A or G of IL10, and –308A or G of TNFA — are identified by a number that refers to its position in the nucleotide sequence upstream (indicated by a minus sign) or downstream (indicated by a plus sign) of the start of the transcription site, followed by a letter indicating the polymorphism, adenine (A), cytosine (C), guanine (G), or thymine (T). The upstream single-nucleotide polymorphisms (at position –511 of IL1B, at position –174 of IL6, at position –592 of IL10, at position –1082 of IL10, and at position –308 of TNFA) are presumed to be located in the promoter region. The +3954 single-nucleotide polymorphism of IL1B is located in the fifth exon of the gene. One of the single-nucleotide polymorphisms — 9261A or G of IL1RA — maps to the second intron of the gene. The number 9261 refers to the locator number of Genbank sequence accession number X64532 (http://www.ncbi.nlm.nih.gov).
Genotyping of Single-Nucleotide Polymorphisms
A multiplex polymerase-chain-reaction–restriction-fragment–length polymorphism (PCR-RFLP) assay was developed for simultaneous typing of the polymorphisms involving position –511 of IL1B, position +3954 of IL1B, and position 9261 of IL1RA by AlwNI-based and TaqI-based RFLP; polymorphisms involving positions –1082 and –592 of IL10 by BslI-based RFLP, and polymorphisms involving position –174 of IL6 and position –308 of TNFA by BslI-based RFLP.8-10 Reagent specificity was confirmed by testing DNA samples from the International Histocompatibility Working Group cytokine gene polymorphism reference panel (http://www.ihwg.org/components/cytokine/cytover.htm). Genotypes of two recently identified single-nucleotide polymorphisms (–3575 and –2763) located in the distal promoter region of the IL10 gene were determined by PCR-RFLP with the use of Tsp509I endonuclease.11
Statistical Analysis
Acute GVHD and chronic GVHD were diagnosed and graded according to standard criteria.12,13 Death in remission was defined as any death occurring before the recurrence of the underlying disease. The cumulative rates of incidence of acute GVHD, chronic GVHD, and death in remission and overall survival were estimated according to the methods of Andersen et al.14 Death was considered to be a competing risk in the analysis of acute and chronic GVHD, and relapse was considered to be a competing risk in the analysis of chronic GVHD and death in remission.
The relations between single-nucleotide–polymorphism genotypes and outcome were evaluated with proportional-hazards regression models, after adjustment for known risk factors. Data on outcomes were censored at the time of a competing event as defined above. Analysis of acute GVHD was adjusted for age at transplantation (as a continuous variable), presence or absence of sex mismatch between donor and recipient, use or nonuse of total-body irradiation in the conditioning regimen, and disease risk group (reason for transplantation). The year of transplantation (1981 through 1991 vs. 1992 through 2000) was also included in the multivariable analysis of acute GVHD because the sensitivity of methods for diagnosing GVHD of the gut increased after 1991. Analysis of chronic GVHD was adjusted for the same risk factors, except for year of transplantation. The analysis of death in remission and overall survival was adjusted for the age at transplantation, the time from diagnosis to transplantation (as a continuous variable), and the disease risk group.
All P values are two-sided and derived from likelihood-ratio statistics from the proportional-hazards regression models. Hazard ratios for the M/m and m/m genotypes were compared with the M/M genotype, the designated reference group, where M represents the more frequent (major) allele and m represents the less frequent (minor) allele in the studied population. Tests for trend were also carried out by assigning the ordinal values 1, 2, and 3 to the genotypes M/M, M/m, and m/m, respectively, and testing the association of the resulting variable with the outcome. Any variable associated with a hazard ratio of 2.0 or greater or of 0.5 or less or a P value for trend of 0.05 or less in the first cohort was reevaluated in the second cohort. No adjustments have been made for multiple comparisons.
Haplotype frequencies and the χ2 test for linkage disequilibrium among pairs of alleles were calculated with use of the Estimating Haplotype-frequencies (EH) program from Rockefeller University (ftp://linkage.rockefeller.edu/software/eh/).15
Results
First Cohort
In the first cohort of 570 recipients, the IL10 –592A allele was significantly associated with a lower incidence of severe (grade III or IV) acute GVHD in both homozygous recipients (those with the A/A genotype) and heterozygous recipients (those with the A/C genotype) (P for trend = 0.003; hazard ratio among patients with the –592A/A and A/C genotypes, as compared with the C/C genotype, 0.5 and 0.5, respectively) (Table 2Table 2
Association of Cytokine Gene Polymorphisms in Recipients and Donors and Grade III or IV Acute Graft-versus-Host Disease (GVHD) in the First Cohort of 570 Transplant Recipients.). A possible association was observed for the IL10 –1082 genotype of the recipient (P for trend = 0.05; hazard ratio associated with the –1082G/G and A/G genotypes, as compared with the A/A genotype, 1.7 and 1.2, respectively) (Table 2). No significant association with severe acute GVHD was detected for IL10 genotypes of the donors, and no significant association was detected for the IL1B –511, IL1B +3954, IL1RA 9261, IL6 –174, or TNFA –308 genotypes in either donors or recipients (Table 2).Second Cohort
In the second cohort of 423 recipients, the hazard ratio for severe GVHD among the 34 recipients with the A/A genotype at the IL10 –592 locus was 0.3 (P for trend = 0.12). Although the small number of recipients with the –592A/A genotype precludes a statistical analysis, the consistency of the effects between the two independent cohorts suggested that the IL10 –592A/A genotype in the recipient was associated with a reduced risk of severe acute GVHD.
IL10 Promoter-Region Genotype and Outcomes of Transplantation
Analysis of polymorphisms in the IL10 promoter region of the recipients and the risk of acute GVHD was next performed in the combined cohort of 993 recipients. Two additional polymorphisms in the IL10 promoter region (–2763 and –3575)11 were evaluated (Table 3Table 3
Association of Interleukin-10 Promoter-Region Genotypes and Grade III or IV Acute Graft-versus-Host Disease (GVHD) in Both Cohorts of 993 Transplant Recipients.). A significant association with a reduced incidence of severe acute GVHD was observed for the IL10 –592A/A genotype, and weak associations with lower incidence were observed for the IL10 –1082A/A and –2763C/C genotypes. Homozygosity for the IL10 –592A allele was associated with the lowest risk of grade III or IV acute GVHD (hazard ratio, 0.4; 95 percent confidence interval, 0.2 to 0.9; P=0.02) (Figure 1AFigure 1Cumulative Incidence of Grade III or IV Acute Graft-versus-Host Disease (GVHD) (Panel A) and Death in Remission (Panel B), According to the Interleukin-10 Genotype at Position –592 among Transplant Recipients.). No significant differences were detected in the distribution of known risk factors for GVHD, including age at transplantation, year of transplantation, presence or absence of sex mismatch between donor and recipient, use or nonuse of total-body irradiation in the conditioning regimen, and disease risk group among patients with the various IL10 –592 genotypes (data not shown).No significant association was found between the recipient's IL10 promoter genotype and the risk of extensive chronic GVHD. Cumulative rates of incidence of extensive chronic GVHD at three years for patients with the IL10 –592A/A, A/C, and C/C genotypes were 38 percent, 38 percent, and 41 percent, respectively.
Death in remission and overall survival among the combined cohort of recipients was also associated with the genotype of the IL10 promoter region. The lowest risk of death in remission was found among recipients who were homozygous for the –592A allele (hazard ratio for the comparison with the C/C genotype, 0.6; 95 percent confidence interval, 0.3 to 1.0; P=0.05). The cumulative rates of incidence of death in remission at three years for recipients with the IL10 –592A/A, A/C, and C/C genotypes were 13 percent, 26 percent, and 25 percent, respectively (Figure 1B). The cumulative rates of incidence of death in remission at three years among recipients with grades 0, I, II, III, and IV acute GVHD were 22 percent, 19 percent, 20 percent, 46 percent, and 96 percent, respectively. The hazard ratio for death in remission after the diagnosis of grade III or IV GVHD was 3.7 (95 percent confidence interval, 2.9 to 4.8; P<0.001). Results for overall survival were similar to those for death in remission. Among recipients with the IL10 –592A/A, A/C, and C/C genotypes, the probability of surviving three years was 71 percent, 56 percent, and 57 percent, respectively.
IL10 Promoter-Region Haplotype
We stratified patients according to IL10 promoter region haplotypes in order to examine the relative effect of the individual haplotype on the risk of severe acute GVHD. Haplotypes are clusters of genetic variants that are inherited as a unit on the same chromosome. Within a population, the individual variants in the IL10 promoter region within such clusters are not randomly distributed; this phenomenon is known as linkage disequilibrium. These nonrandom distributions make possible the identification of haplotypes in the IL10 promoter region. Previous studies have identified at least two clusters of single-nucleotide polymorphisms in the 5' flanking region of the IL10 gene, one at the distal positions –3575 and –2763, and the other at the proximal positions –1082, –819, and –59211,16 (Figure 2Figure 2
A Map of the Interleukin-10 Gene and 5' Upstream Promoter Region (Panel A) and the Six Five-Locus Interleukin-10 Promoter-Region Haplotypes Identified in the Combined Cohort of 993 Patients and Their Estimated Frequencies (Panel B).). There is linkage disequilibrium between the –819 single-nucleotide polymorphism (T or C allele) and the –592 single-nucleotide polymorphism (A or C allele), with only two haplotypes observed at reasonable frequencies. In one, –819T is linked to –592A (the T-A haplotype), and in the other, –819C is linked to –592C (the C-C haplotype).Haplotype frequencies among the combined population of 993 transplant recipients were estimated as previously described.15 The results were consistent with previous findings.11,16 In the resulting model (assuming complete linkage disequilibrium between –819 and –592), we found that the five single-nucleotide polymorphisms segregated as six distinct haplotypes with frequencies of 4 percent or greater: T-C-A-T-A, T-C-A-C-C, T-C-G-C-C, A-C-G-C-C, T-A-G-C-C, and A-A-G-C-C (Figure 2). The proximal A-T-A haplotype (or the –592A allele) and the A-C-C haplotype were associated exclusively with the distal T-C haplotype to form the extended IL10 promoter T-C-A-T-A and T-C-A-C-C haplotypes, respectively. The proximal G-C-C haplotype is found together with the distal T-C, A-C, T-A, and A-A haplotypes to form the extended T-C-G-C-C, A-C-G-C-C, T-A-G-C-C, and A-A-G-C-C haplotypes (Figure 2).
Associations with severe acute GVHD were first evaluated in patients classified according to three proximal promoter haplotypes (A-T-A, A-C-C, and G-C-C), defined by single-nucleotide polymorphisms in positions –1082, –819, and –592. Among the six resulting genotypes, the incidence of severe acute GVHD was lowest in the group that was homozygous for A-T-A (9 percent for genotype A-T-A/A-T-A), intermediate in the two groups that were heterozygous for A-T-A (13 percent and 16 percent for genotypes A-T-A/A-C-C and A-T-A/G-C-C, respectively), and highest in the three groups without A-T-A (20 percent, 21 percent, and 22 percent for genotypes G-C-C/G-C-C, A-C-C/A-C-C, and A-C-C/G-C-C, respectively) (Table 4Table 4
Analysis of the Risk of Graft-versus-Host Disease (GVHD) According to the Proximal Interleukin-10 Promoter-Region Haplotypes of the Recipients.).When the three genotypes defined by the A-T-A and A-C-C haplotypes were compared, the A-T-A/A-T-A genotype was associated with a lower risk of severe acute GVHD than were the A-T-A/A-C-C and A-C-C-/A-C-C genotypes (P for trend = 0.03). When the three genotypes consisting of the A-T-A and G-C-C haplotypes were compared, the A-T-A/A-T-A genotype was associated with a lower risk of severe acute GVHD than were the A-T-A/G-C-C and G-C-C/G-C-C genotypes (P for trend = 0.03). Together with the extended haplotype analysis (Figure 2), these data suggest that the proximal A-T-A haplotype (extended T-C-A-T-A haplotype) conveys a lower risk of severe acute GVHD than the proximal A-C-C haplotype (extended T-C-A-C-C haplotype) or proximal G-C-C haplotype (extended T-C-G-C-C, A-C-G-C-C, T-A-G-C-C, or A-A-G-C-C haplotype).
Dominant Effect of IL10–592 Genotype
When the analysis was limited to recipients with the IL10 –592C/C genotype, the incidence of severe acute GVHD in recipients with –1082G/G, A/A, or A/G was similar (20 to 22 percent) (Table 4). When the analysis was limited to recipients with the –1082A/A genotype, the incidence of severe acute GVHD was 9 percent among recipients with the –592A/A genotype, 13 percent among those with the –592A/C genotype, and 21 percent among those with the –592C/C genotype. Results were similar when analyses were stratified for –592 and either the distal –2763 or –3575 polymorphism (data not shown).
A multivariable analysis adjusted for the –592 genotype indicated that polymorphisms at –1082, –2763, or –3575 were not independent risk factors for severe acute GVHD (P for trend = 0.98, 0.67, and 0.59, respectively). In contrast, the P values for trend for –592 remained significant when the analysis was adjusted for the –1082, –2763, or –3575 genotype (P=0.005, 0.005, and 0.002, respectively). Although these results are consistent with the hypothesis that the –592 polymorphism in this population has a dominant effect on the outcome of transplantation, the data cannot be used to distinguish whether this single nucleotide (–592A allele) or an extended sequence (T-C-A-T-A haplotype) accounts for the observed functional effect.
Discussion
Previous studies have suggested an association between polymorphisms in the IL1RA, IL6, IL10, TNFA, and interferon-γ genes and the outcome of hematopoietic stem-cell transplantation.17-21 The results, however, have been inconsistent, probably because of heterogeneity among the patients, the relatively small numbers of patients in individual studies, and potential statistical problems associated with multiple comparisons. We were able to confirm and extend the previous findings that polymorphisms in the IL10 promoter region in transplant recipients have a significant effect on the outcome of hematopoietic-cell transplantation.
We found that a specific IL10 promoter-region haplotype had a protective effect. The lowest incidence of severe acute GVHD and death in remission was associated with homozygosity for the T-C-A-T-A (–3575/–2763/–1082/–819/–592) haplotype. The –592A allele was found to be in complete linkage disequilibrium with the rest of the T-C-A-T-A haplotype, allowing this single-nucleotide polymorphism to serve as a convenient “marker tag” for the genetic elements associated with the observed clinical outcomes.22 The mechanism underlying the lower incidence of acute GVHD and death in remission among recipients who were homozygous for the T-C-A-T-A haplotype and the molecular effects of the nucleotide variation in the IL10 promoter region are not precisely known. A full understanding of gene function will require more detailed knowledge of the interactions between specific IL10 transcription factors and the various IL10 promoter-region haplotypes.
Interleukin-10 is a potent suppressor of TNF-α, interleukin-1α, interleukin-1β, interleukin-6, interleukin-12, and interferon-γ production and may facilitate the induction of tolerance after allogeneic transplantation.23-29 The administration of exogenous interleukin-10, however, has variable effects in murine models of GVHD.30,31 Blazer et al. have reported a dose-dependent effect of interleukin-10 on the lethality of GVHD in mice. High doses potentiated GVHD, whereas lower doses were protective.32 Clinical studies, however, suggest that elevated levels of endogenous interleukin-10 may be associated with immunologic tolerance. Bacchetta et al.33 observed an association between increased expression of the IL10 gene in recipient-derived monocytes and the absence of GVHD after the receipt of HLA-mismatched fetal hematopoietic cells among patients with severe combined immunodeficiency. Holler et al.34 have reported that elevated levels of endogenous interleukin-10 before transplantation are associated with a reduced risk of GVHD. These data suggest that endogenous interleukin-10 production soon after transplantation may facilitate the suppression of alloimmune responses.
Conflicting results have been reported regarding the genetic control of interleukin-10 production.11,16,35-37 Increased production of interleukin-10 by peripheral-blood mononuclear cells has been associated with the –1082G allele or the G-C-C (–1082/–819/–592) haplotype16,35; however, Keijsers et al.36 reported that the –1082G allele, or G-C-C haplotype, was associated with a decreased production of interleukin-10. This finding has been supported by a more recent report by Gibson et al.11 that the distal promoter region A-A (–3575/–2763) haplotype was associated with the proximal G-C-C (–1082/–819/–592) promoter haplotype. They also found decreased production of interleukin-10 in vitro among patients with the distal A-A haplotype. The results of these two studies suggest that the A-A-G-C-C haplotype is associated with decreased production of interleukin-10 (Figure 2). The estimated haplotype frequencies in our study population were essentially the same as those described by Gibson et al.11 The distal A-A promoter haplotype was linked to the proximal G-C-C haplotype, and the proximal A-T-A and A-C-C haplotypes were each linked to the distal T-C haplotype. The –592A allele was found only in recipients with the T-C-A-T-A haplotype. In our study, recipients homozygous for the IL10 T-C-A-T-A haplotype had a lower risk of acute GVHD than recipients who were heterozygous for the T-C-A-T-A or T-C-A-C-C haplotype or recipients who were homozygous for the T-C-A-C-C haplotype. Together with the reported biologic functions of interleukin-10 in vitro and in vivo,23,34 these data suggest that the T-C-A-T-A haplotype is defined by high levels of interleukin-10.
Japanese patients have a lower incidence of acute GVHD than do white patients after the receipt of cells from either HLA-matched siblings or unrelated donors.38,39 This difference has been assumed to reflect a lower degree of diversity for HLA and minor histocompatibility antigens among Japanese. However, the frequency of the IL10 –592A allele is 67 percent in the Japanese population40 and 70 percent in the Taiwanese populations (Tseng L-H: unpublished data), both of which are much higher than the frequency of 23 percent and 24 percent previously reported in two white populations.35,37 These data suggest that the higher frequency of the –592A allele in the Japanese population may explain the lower incidence of GVHD among Japanese transplant recipients. Variation in the IL10 gene polymorphisms may be one of the factors that account for differences in the incidence and severity of disease among various populations.
Despite recent advances in supportive care, severe grade III or IV GVHD remains a serious complication of transplantation and contributes to transplantation-related mortality. On the basis of the results of previous in vivo and in vitro studies and our own clinical correlations, we hypothesize that a high level of interleukin-10 production by recipients' cells during the early post-transplantation period mitigates the intensity of the alloimmune response and GVHD-induced inflammation, thereby reducing the clinical manifestations of GVHD and associated mortality. Knowledge of the IL10 promoter-region genotypes and, possibly, of polymorphisms in other immune regulatory genes, could be incorporated into the pretransplantation risk-assessment process and serve as a guide for the planning of treatment. The use of alternative approaches, such as nonablative conditioning regimens, might reduce morbidity and mortality in selected high-risk patients. Further insight into the mechanism underlying the association between the IL10 promoter-region genotype and GVHD could prompt new strategies for modulating the intensity of the alloimmune response and reducing the toxicity of GVHD.
Supported by grants (AI33484, AI49213, CA18029, CA15704, and CA18221) from the National Institutes of Health.
Source Information
From the Fred Hutchinson Cancer Research Center (M.-T.L., B.S., P.J.M., T.G., J.A.H.) and the University of Washington, School of Medicine (P.J.M., J.A.H.) — both in Seattle; and the Department of Medical Genetics, National Taiwan University Hospital (L.-H.T., P.-J.C.), and the College of Medicine, Graduate Institutes of Clinical Medicine (P.-J.C.), and Cancer Research Center (M.-T.L.), National Taiwan University — both in Taipei, Taiwan.
Address reprint requests to Dr. Hansen at the Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., D2-100, P.O. Box 19024, Seattle, WA 98109-1024, or at jhansen@fhcrc.org.
- References
References
1
Ferrara JLM ,Deeg HJ . Graft-versus-host disease. N Engl J Med 1991;324:667-674
Full Text | Web of Science | Medline2
Beatty PG ,Clift RA ,Mickelson EM , et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313:765-771
Full Text | Web of Science | Medline3
Perreault C ,Decary F ,Brochu S ,Gyger M ,Belanger R ,Roy D . Minor histocompatibility antigens. Blood 1990;76:1269-1280
Web of Science | Medline4
Krenger W ,Hill GR ,Ferrara JLM . Cytokine cascades in acute graft-versus-host disease. Transplantation 1997;64:553-558
CrossRef | Web of Science | Medline5
Bidwell J ,Keen L ,Gallagher G , et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999;1:3-19
CrossRef | Web of Science | Medline6
Hansen JA, Mickelson EM, Choo SY, et al. Clinical bone marrow transplantation: donor selection and recipient monitoring. In: Rose MR, de Macario EC, Fahey JL, Friedman H, Penn GM, eds. Manual of clinical laboratory immunology. 4th ed. Washington, D.C.: American Society for Microbiology, 1992:850-66.
7
Lin MT ,Gooley T ,Hansen JA , et al. Absence of statistically significant correlation between disparity for the minor histocompatibility antigen-HA-1 and outcome after allogeneic hematopoietic cell transplantation. Blood 2001;98:3172-3173
CrossRef | Web of Science | Medline8
Tseng L-H ,Chen P-J ,Lin M-T , et al. Simultaneous genotyping of single nucleotide polymorphisms in the IL-6, IL10, TNFα and TNFβ genes. Tissue Antigens 2002;59:280-286
CrossRef | Web of Science | Medline9
Tseng L-H ,Chen P-J ,Lin M-T , et al. Simultaneous genotyping of single nucleotide polymorphisms in the IL-1 gene complex by multiplex-polymerase chain reaction-restriction fragment length polymorphism. J Immunol Methods 2002;267:151-156
CrossRef | Web of Science | Medline10
Tseng L-H ,Chen P-J ,Lin M-T , et al. Single nucleotide polymorphisms in intron 2 of the human interleukin-1 receptor antagonist (IL1RA) gene: further definition of the IL-1 beta and IL1RA polymorphisms in North American Caucasians and Taiwanese Chinese. Tissue Antigens 2001;57:318-324
CrossRef | Web of Science | Medline11
Gibson AW ,Edberg JC ,Wu J ,Westendorp RG ,Huizinga TW ,Kimberly RP . Novel single nucleotide polymorphisms in the distal IL10 promoter affect IL10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001;166:3915-3922
Web of Science | Medline12
Przepiorka D ,Weisdorf D ,Martin P , et al. 1994 Consensus conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-828
Web of Science | Medline13
Sullivan KM ,Agura E ,Anasetti C , et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250-259
Web of Science | Medline14
Andersen PK, Borgan Ø, Gill RD, Keiding N. Statistical models based on counting processes. New York: Springer-Verlag, 1993.
15
Organization of genetic variation. In: Hartl DL, Clark AG. Principles of population genetics. 3rd ed. Sunderland, Mass.: Sinauer, 1997:71-109.
16
Turner DM ,Williams DM ,Sankaran D ,Lazarus M ,Sinnott PJ ,Hutchinson IV . An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8
CrossRef | Medline17
Cavet J ,Middleton PG ,Segall M ,Noreen H ,Davies SM ,Dickinson AM . Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999;94:3941-3946
Web of Science | Medline18
Cullup H ,Dickinson AM ,Jackson GH ,Taylor PR ,Cavet J ,Middleton PG . Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 2001;113:807-813
CrossRef | Web of Science | Medline19
Takahashi H ,Furukawa T ,Hashimoto S , et al. Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant 2000;26:1317-1323
CrossRef | Web of Science | Medline20
Socie G ,Loiseau P ,Tamouza R , et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2001;72:699-706
CrossRef | Web of Science | Medline21
Cavet J ,Dickinson AM ,Norden J ,Taylor PR ,Jackson GH ,Middleton PG . Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001;98:1594-1600
CrossRef | Web of Science | Medline22
Gabriel SB ,Schaffner SF ,Nguyen H , et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-2229
CrossRef | Web of Science | Medline23
Fiorentino DF ,Zlotnik A ,Mosmann TR ,Howard M ,O'Garra A . IL10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-3822
Web of Science | Medline24
Ding L ,Linsley PS ,Huang LY ,Germain RN ,Shevach EM . IL10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993;151:1224-1234
Web of Science | Medline25
Groux H ,Bigler M ,de Vries JE ,Roncarolo MG . Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996;184:19-29
CrossRef | Web of Science | Medline26
Levings MK ,Sangregorio R ,Galbiati F ,Squadrone S ,de Waal Malefyt R ,Roncarolo MG . IFN-α and IL10 induce the differentiation of human type 1 T regulatory cells. J Immunol 2001;166:5530-5539
Web of Science | Medline27
Zeller JC ,Panoskaltsis-Mortari A ,Murphy WJ , et al. Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL10 and TGF-beta. J Immunol 1999;163:3684-3691
Web of Science | Medline28
Taylor PA ,Lees CJ ,Blazar BR . The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002;99:3493-3499
CrossRef | Web of Science | Medline29
Hoffmann P ,Ermann J ,Edinger M ,Fathman CG ,Strober S . Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196:389-399
CrossRef | Web of Science | Medline30
Smith SR ,Terminelli C ,Pennline KJ ,Kenworthy-Bott L ,Donkin J ,Calzetta A . Inhibitory effects of recombinant human interleukin 10 on disease manifestations in a P→F1 model of acute graft versus host disease. Transplantation 1995;59:890-896
CrossRef | Web of Science | Medline31
Blazar BR ,Taylor PA ,Smith S ,Vallera DA . Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995;85:842-851
Web of Science | Medline32
Blazar BR ,Taylor PA ,Panoskaltsis-Mortari A , et al. Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease. Transplantation 1998;66:1220-1229
CrossRef | Web of Science | Medline33
Bacchetta R ,Bigler M ,Touraine JL , et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients with HLA mismatched hematopoietic stem cells. J Exp Med 1994;179:493-502
CrossRef | Web of Science | Medline34
Holler E ,Roncarolo MG ,Hintermeier-Knabe R , et al. Prognostic significance of increased IL10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;25:237-241
CrossRef | Web of Science | Medline35
Crawley E ,Kay R ,Sillibourne J ,Patel P ,Hutchinson I ,Woo P . Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999;42:1101-1108
CrossRef | Web of Science | Medline36
Keijsers V ,Verweij CL ,Westendorp RGJ ,Breedveld FC ,Huizinga TWJ . IL10 polymorphisms in relation to production and rheumatoid arthritis. Arthritis Rheum 1997;40:Suppl:S179-S179 abstract.
CrossRef | Web of Science37
Koss K ,Satsangi J ,Fanning GC ,Welsh KI ,Jewell DP . Cytokine (TNFα, LTα and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2000;1:185-190
CrossRef | Web of Science | Medline38
Morishima Y ,Morishita Y ,Tanimoto M , et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings: possible role of genetic homogeneity. Blood 1989;74:2252-2256
Web of Science | Medline39
Sasazuki T ,Juji T ,Morishima Y , et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor: Japan Marrow Donor Program. N Engl J Med 1998;339:1177-1185[Erratum, N Engl J Med 1999;340:402.]
Full Text | Web of Science | Medline40
Tegoshi H ,Hasegawa G ,Obayashi H , et al. Polymorphisms of interferon-gamma gene CA-repeat and interleukin-10 promoter region (-592A/C) in Japanese type I diabetes. Hum Immunol 2002;63:121-128
CrossRef | Web of Science | Medline
- Citing Articles (128)
Citing Articles
1
Boyoon Choi, Dong Eun Lee, Hyo Young Park, Sohyun Jeong, Sang-Min Lee, Eunhee Ji, Seonyang Park, Jung Mi Oh. (2012) A Meta-Analysis of the Effects of Interleukin-6 −174 G>C Genetic Polymorphism on Acute Graft-Versus-Host Disease Susceptibility. Clinical Therapeutics
CrossRef2
Shanmugaapriya Sellathamby, Kavitha M. Lakshmi, Marc Busson, Auro Viswabandya, Biju George, Vikram Mathews, Mammen Chandy, Dominique Charron, Rajagopal Krishnamoorthy, Ryad Tamouza, Alok Srivastava. (2012) Polymorphisms in the immunoregulatory genes are associated with hematopoietic recovery and increased susceptibility to bacterial infections in patients with thalassaemia major undergoing matched related hematopoietic stem cell transplantation (HSCT). Biology of Blood and Marrow Transplantation
CrossRef3
Y Mori, T Teshima, K Kamezaki, K Kato, K Takenaka, H Iwasaki, T Miyamoto, K Nagafuji, T Eto, K Akashi. (2011) Validation of pretransplantation assessment of mortality risk score in the outcome of hematopoietic SCT in non-Caucasians. Bone Marrow Transplantation
CrossRef4
M Murase, T Nishida, M Onizuka, Y Inamoto, K Sugimoto, N Imahashi, M Murata, K Miyamura, Y Kodera, H Inoko, T Naoe. (2011) Cytotoxic T-lymphocyte antigen 4 haplotype correlates with relapse and survival after allogeneic hematopoietic SCT. Bone Marrow Transplantation 46:11, 1444-1449
CrossRef5
Smita Bhatia, Stella M. Davies, K. Scott Baker, Michael A. Pulsipher, John A. Hansen. (2011) NCI, NHLBI First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Etiology and Pathogenesis of Late Effects after HCT Performed in Childhood—Methodologic Challenges. Biology of Blood and Marrow Transplantation 17:10, 1428-1435
CrossRef6
J.-M. Tiercy. (2011) Immunogenetics of hematopoietic stem cell transplantation: the contribution of microsatellite polymorphism studies. International Journal of Immunogenetics 38:5, 365-372
CrossRef7
Ines Cilenšek, Amela Hercegovac, Jovana Nikolajević Starčević, Katarina Vukojević, Mirna Saraga Babić, Aleksandra Milutinović Živin. (2011) Polymorphisms of interleukin-4, -10 and 12B genes and diabetic retinopathy. Central European Journal of Biology 6:4, 558-564
CrossRef8
STEPHANIE W. HU, JONATHAN COTLIAR. (2011) Acute graft-versus-host disease following hematopoietic stem-cell transplantation. Dermatologic Therapy 24:4, 411-423
CrossRef9
Yasuo Mori, Toshihiro Miyamoto, Koji Kato, Kenjiro Kamezaki, Takuro Kuriyama, Seido Oku, Katsuto Takenaka, Hiromi Iwasaki, Naoki Harada, Motoaki Shiratsuchi, Yasunobu Abe, Koji Nagafuji, Takanori Teshima, Koichi Akashi. (2011) Different Risk Factors Related to Adenovirus- or BK Virus-Associated Hemorrhagic Cystitis following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation
CrossRef10
Richard Maier, Iris Steinbrugger, Anton Haas, Maksida Selimovic, Wilfried Renner, Yosuf El-Shabrawi, Christoph Werner, Andreas Wedrich, Otto Schmut, Martin Weger. (2011) Role of Inflammation-Related Gene Polymorphisms in Patients with Central Retinal Vein Occlusion. Ophthalmology 118:6, 1125-1129
CrossRef11
Diana M. Girnita, Erin L. Ohmann, Maria M. Brooks, Steven A. Webber, Gilbert J. Burckart, Robert E. Ferrell, Sarangarajan Ranganathan, Richard Chinnock, Charles Canter, Linda Addonizio, Daniel Bernstein, James K. Kirklin, David C. Naftel, Adriana Zeevi. (2011) Gene Polymorphisms Impact the Risk of Rejection With Hemodynamic Compromise: A Multicenter Study. Transplantation 91:12, 1326-1332
CrossRef12
Tsuyoshi Tanabe, Natsu Yamaguchi, Koichi Matsuda, Keiko Yamazaki, Satoshi Takahashi, Arinobu Tojo, Makoto Onizuka, Yoshinobu Eishi, Hideki Akiyama, Jun Ishikawa, Takehiko Mori, Masamichi Hara, Kazutoshi Koike, Keisei Kawa, Takakazu Kawase, Yasuo Morishima, Hiroki Amano, Mikiko Kobayashi-Miura, Takeyasu Kakamu, Yusuke Nakamura, Shigetaka Asano, Yasuyuki Fujita. (2011) Association analysis of the NOD2 gene with susceptibility to graft-versus-host disease in a Japanese population. International Journal of Hematology 93:6, 771-778
CrossRef13
Maria-Grazia Roncarolo, Silvia Gregori, Barbarella Lucarelli, Fabio Ciceri, Rosa Bacchetta. (2011) Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunological Reviews 241:1, 145-163
CrossRef14
Evgenios Goussetis, Ioanna Varela, Ioulia Peristeri, Vasiliki Kitra, Kleopatra Spanou, Olga Moraloglou, Anna Paisiou, Sofia Karatasaki, Alexandra Soldatou, Nikki Constantinidou, Stelios Graphakos. (2011) Cytokine gene polymorphisms and graft-versus-host disease in children after matched sibling hematopoietic stem cell transplantation: a single-center experience. Cellular and Molecular Immunology 8:3, 276-280
CrossRef15
Haowen Xiao, Weijie Cao, Xiaoyu Lai, Yi Luo, Jimin Shi, Yamin Tan, Jingsong He, Wanzhuo Xie, Xiaojian Meng, Weiyan Zheng, Gaofeng Zheng, Xiaoyan Han, Lai Jin, Lifei Zhang, Yingjia Wang, Xiaohong Yu, Zhen Cai, Maofang Lin, Xiujin Ye, He Huang. (2011) Immunosuppressive Cytokine Gene Polymorphisms and Outcome after Related and Unrelated Hematopoietic Cell Transplantation in a Chinese Population. Biology of Blood and Marrow Transplantation 17:4, 542-549
CrossRef16
H W Xiao, X Y Lai, Y Luo, J M Shi, Y M Tan, J S He, W Z Xie, L Li, X L Zhu, J J Zhu, J Sun, G Q Wei, L Jin, L Z Liu, K N Wu, X H Yu, Z Cai, M F Lin, X J Ye, H Huang. (2011) Relationship between TNFA, TNFB and TNFRII gene polymorphisms and outcome after unrelated hematopoietic cell transplantation in a Chinese population. Bone Marrow Transplantation 46:3, 400-407
CrossRef17
Oussama Kebir, Mohamed-Ali Gorsane, Lisa Blecha, Marie-Odile Krebs, Michel Reynaud, Amine Benyamina. (2011) Association of Inflammation Genes with Alcohol Dependence/Abuse: A Systematic Review and a Meta-Analysis. European Addiction Research 17:3, 146-153
CrossRef18
Hsin-Bang Leu, Chia-Min Chung, Shao-Yuan Chuang, Chyi-Huey Bai, Jiunn-Rong Chen, Jaw-Wen Chen, Wen-Harn Pan. (2011) Genetic variants of connexin37 are associated with carotid intima-medial thickness and future onset of ischemic stroke. Atherosclerosis 214:1, 101-106
CrossRef19
Laura F. Newell, Ted Gooley, John A. Hansen, Derek L. Stirewalt, Effie W. Petersdorf, H. Joachim Deeg. (2010) Tumor Necrosis Factor Polymorphism Affects Transplantation Outcome in Patients with Myelodysplastic Syndrome but Not in Those with Chronic Myelogenous Leukemia, Independent of the Presence of HLA-DR15. Biology of Blood and Marrow Transplantation 16:12, 1700-1706
CrossRef20
John A Hansen, Jason W Chien, Edus H Warren, Lue Ping Zhao, Paul J Martin. (2010) Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. Current Opinion in Hematology 17:6, 483-492
CrossRef21
E. Garza-González, G. I. Pérez-Pérez, S. I. Mendoza-Ibarra, J. P. Flores-Gutiérrez, F. J. Bosques-Padilla. (2010) Genetic risk factors for inflammatory bowel disease in a North-eastern Mexican population. International Journal of Immunogenetics 37:5, 355-359
CrossRef22
Surendra Sharma, Joan Stabila, Linda Pietras, Arvind R. Singh, Bethany McGonnigal, Jan Ernerudh, Leif Matthiesen, James F. Padbury. (2010) Haplotype-dependent Differential Activation of the Human IL-10 Gene Promoter in Macrophages and Trophoblasts: Implications for Placental IL-10 Deficiency and Pregnancy Complications. American Journal of Reproductive Immunology 64:3, 179-187
CrossRef23
A. M. S. Muller, J. A. Linderman, M. Florek, D. Miklos, J. A. Shizuru. (2010) Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proceedings of the National Academy of Sciences 107:33, 14721-14726
CrossRef24
M Arora, B Lindgren, S Basu, S Nagaraj, M Gross, D Weisdorf, B Thyagarajan. (2010) Polymorphisms in the base excision repair pathway and graft-versus-host disease. Leukemia 24:8, 1470-1475
CrossRef25
Beatriz Martín-Antonio, Miquel Granell, Álvaro Urbano-Ispizua. (2010) Genomic polymorphisms of the innate immune system and allogeneic stem cell transplantation. Expert Review of Hematology 3:4, 411-427
CrossRef26
Anna-Maria Georgoudaki, Tolga Sutlu, Evren Alici. (2010) Suicide gene therapy for graft-versus-host disease. Immunotherapy 2:4, 521-537
CrossRef27
Rakesh K. Goyal, Yan Lin, Kirk R. Schultz, Robert E. Ferrell, Yeonhee Kim, Liane Fairfull, Elayne Livote, Gregory Yanik, Mark Atlas. (2010) Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow Transplantation in Children: A Pediatric Blood and Marrow Transplant Consortium Study. Biology of Blood and Marrow Transplantation 16:7, 927-936.e1
CrossRef28
Jessica E. Thaxton, Surendra Sharma. (2010) Interleukin-10: A Multi-Faceted Agent of Pregnancy. American Journal of Reproductive Immunology 63:6, 482-491
CrossRef29
Renata Gonçalves Resende, Jeane de Fátima Correia-Silva, Telma Cristina Arão, Tarcília Aparecida Silva, Mauro Henrique Nogueira Guimarães Abreu, Henrique Bittencourt, Ricardo Santiago Gomez. (2010) Investigation of Functional IL-10 Gene Polymorphism and IL-10 Levels in Acute Graft-Versus-Host Disease. Journal of Clinical Immunology 30:3, 465-473
CrossRef30
O. Ostrovsky, A. Shimoni, A. Rand, I. Vlodavsky, A. Nagler. (2010) Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. Blood 115:11, 2319-2328
CrossRef31
Lorenzo Cosmi, Francesco Liotta, Francesco Annunziato. 2010. T Lymphocyte Responses: Development. .
CrossRef32
Sung W. Choi, John E. Levine, James L.M. Ferrara. (2010) Pathogenesis and Management of Graft-versus-Host Disease. Immunology and Allergy Clinics of North America 30:1, 75-101
CrossRef33
Armin Gerger, Wilfried Renner, Tanja Langsenlehner, Günter Hofmann, Gudrun Knechtel, Joanna Szkandera, Hellmut Samonigg, Peter Krippl, Uwe Langsenlehner. (2010) Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Research and Treatment 119:3, 701-705
CrossRef34
Y Inamoto, M Murata, A Katsumi, Y Kuwatsuka, A Tsujimura, Y Ishikawa, K Sugimoto, M Onizuka, S Terakura, T Nishida, T Kanie, H Taji, H Iida, R Suzuki, A Abe, H Kiyoi, T Matsushita, K Miyamura, Y Kodera, T Naoe. (2010) Donor single nucleotide polymorphism in the CCR9 gene affects the incidence of skin GVHD. Bone Marrow Transplantation 45:2, 363-369
CrossRef35
A. Shimabukuro-Vornhagen, M. J. Hallek, R. F. Storb, M. S. von Bergwelt-Baildon. (2009) The role of B cells in the pathogenesis of graft-versus-host disease. Blood 114:24, 4919-4927
CrossRef36
Nicola Gagliani, Alessandra Ferraro, Maria Grazia Roncarolo, Manuela Battaglia. (2009) Autoimmune diabetic patients undergoing allogeneic islet transplantation: are we ready for a regulatory T-cell therapy?. Immunology Letters 127:1, 1-7
CrossRef37
G. Socie, B. R. Blazar. (2009) Acute graft-versus-host disease: from the bench to the bedside. Blood 114:20, 4327-4336
CrossRef38
S. Nishiwaki, S. Terakura, M. Ito, T. Goto, A. Seto, K. Watanabe, M. Yanagisawa, N. Imahashi, S. Tsukamoto, M. Shimba, Y. Ozawa, K. Miyamura. (2009) Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease. Blood 114:14, 3113-3116
CrossRef39
Susan E Conway, Reza Abdi. (2009) Immunoregulatory gene polymorphisms and graft-versus-host disease. Expert Review of Clinical Immunology 5:5, 523-534
CrossRef40
A H Elmaagacli, M Koldehoff, D W Beelen. (2009) Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9. Bone Marrow Transplantation 44:5, 295-302
CrossRef41
James LM Ferrara, John E Levine, Pavan Reddy, Ernst Holler. (2009) Graft-versus-host disease. The Lancet 373:9674, 1550-1561
CrossRef42
Cortney V Jones, Edward A Copelan. (2009) Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation. Future Oncology 5:4, 559-568
CrossRef43
Christine N Duncan. (2009) Impact of donor characteristics in survival and graft-versus-host disease following pediatric hematopoietic stem cell transplant. Pediatric Health 3:2, 181-189
CrossRef44
David Michonneau, Régis Peffault de Latour, Raphaël Porcher, Marie Robin, Marc Benbunan, Vanderson Rocha, Patricia Ribaud, Christele Ferry, Agnes Devergie, Valérie Vanneaux, Eliane Gluckman, Jean Pierre Marolleau, Gérard Socié, Jérôme Larghero. (2009) Influence of bone marrow graft B lymphocyte subsets on outcome after HLA-identical sibling transplants. British Journal of Haematology 145:1, 107-114
CrossRef45
V Rocha, R Porcher, J F Fernandes, A Filion, H Bittencourt, W Silva, G Vilela, D L Zanette, C Ferry, J Larghero, A Devergie, P Ribaud, Y Skvortsova, R Tamouza, E Gluckman, G Socie, M A Zago. (2009) Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 23:3, 545-556
CrossRef46
Li-Hui Tseng, Barry Storer, Effie Petersdorf, Ming-Tseh Lin, Jason W. Chien, Bryan M. Grogan, Mari Malkki, Pei-Jer Chen, Lue P. Zhao, Paul J. Martin, John A. Hansen. (2009) IL10 and IL10 Receptor Gene Variation and Outcomes After Unrelated and Related Hematopoietic Cell Transplantation. Transplantation 87:5, 704-710
CrossRef47
John A. Hansen. (2009) Genomic and Proteomic Analysis of Allogeneic Hematopoietic Cell Transplant Outcome. Seeking Greater Understanding the Pathogenesis of GVHD and Mortality. Biology of Blood and Marrow Transplantation 15:1, e1-e7
CrossRef48
K. A. Markey, K. P. A. MacDonald, G. R. Hill. (2008) Impact of cytokine gene polymorphisms on graft- vs -host disease. Tissue Antigens 72:6, 507-516
CrossRef49
Claudio Anasetti. (2008) What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?. Best Practice & Research Clinical Haematology 21:4, 691-697
CrossRef50
Effie W Petersdorf, John A Hansen. (2008) New advances in hematopoietic cell transplantation. Current Opinion in Hematology 15:6, 549-554
CrossRef51
Bochud, Pierre-Yves, Chien, Jason W., Marr, Kieren A., Leisenring, Wendy M., Upton, Arlo, Janer, Marta, Rodrigues, Stephanie D.Li, SarahHansen, John A., Zhao, Lue Ping, Aderem, Alan, Boeckh, Michael, . (2008) Toll-like Receptor 4 Polymorphisms and Aspergillosis in Stem-Cell Transplantation. New England Journal of Medicine 359:17, 1766-1777
Full Text52
John Koreth, Joseph H Antin. (2008) Current and future approaches for control of graft-versus-host disease. Expert Review of Hematology 1:1, 111-128
CrossRef53
Diana M Girnita, Gilbert Burckart, Adriana Zeevi. (2008) Effect of cytokine and pharmacogenomic genetic polymorphisms in transplantation. Current Opinion in Immunology 20:5, 614-625
CrossRef54
Miguel Alcoceba, Ana Balanzategui, Maria Díez-Campelo, Patricia Martín-Jiménez, Maria Eugenia Sarasquete, M Carmen Chillón, Carlos Santamaría, Jose Antonio Pérez-Simón, Luis Marín, M Dolores Caballero, Jesús F. San Miguel, Ramón García-Sanz, Marcos González. (2008) Clinical and Prognostic Value of Discrepancies in Microsatellite DNA Regions Between Recipient and Donor in Human Leukocyte Antigen-Identical Allogeneic Transplantation Setting. Transplantation 86:7, 983-990
CrossRef55
Jason E. Foley, Jacopo Mariotti, Kaitlyn Ryan, Michael Eckhaus, Daniel H. Fowler. (2008) Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL-10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells. Biology of Blood and Marrow Transplantation 14:9, 959-972
CrossRef56
Josep Grinyó, Yves Vanrenterghem, Björn Nashan, Flavio Vincenti, Henrik Ekberg, Klaus Lindpaintner, Michelle Rashford, Clare Nasmyth-Miller, Athina Voulgari, Olivia Spleiss, Matthew Truman, Laurent Essioux. (2008) Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transplant International 21:9, 879-891
CrossRef57
John Bladon, Peter Taylor. (2008) Extracorporeal Photopheresis Normalizes Some Lymphocyte Subsets (Including T Regulatory Cells) in Chronic Graft-Versus-Host-Disease. Therapeutic Apheresis and Dialysis 12:4, 311-318
CrossRef58
Yoon Kyong Choi, Joanne Kwak-Kim. (2008) REVIEW ARTICLE: Cytokine Gene Polymorphisms in Recurrent Spontaneous Abortions: A Comprehensive Review. American Journal of Reproductive Immunology 60:2, 91-110
CrossRef59
A. M. Dickinson. (2008) Non-HLA genetics and predicting outcome in HSCT. International Journal of Immunogenetics 35:4-5, 375-380
CrossRef60
A.M. Dickinson, E. Holler. (2008) Polymorphisms of cytokine and innate immunity genes and GVHD. Best Practice & Research Clinical Haematology 21:2, 149-164
CrossRef61
S. Wieczorek, B. Hellmich, L. Arning, F. Moosig, P. Lamprecht, W. L. Gross, J. T. Epplen. (2008) Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis. Arthritis & Rheumatism 58:6, 1839-1848
CrossRef62
Tomomi Toubai, Yaping Sun, Pavan Reddy. (2008) GVHD pathophysiology: is acute different from chronic?. Best Practice & Research Clinical Haematology 21:2, 101-117
CrossRef63
M. Marcos, I. Pastor, R. GonzAlez-Sarmiento, F. J. Laso. (2008) Interleukin-10 Gene Polymorphism is Associated with Alcoholism but not With Alcoholic Liver Disease. Alcohol and Alcoholism 43:5, 523-528
CrossRef64
John A. Hansen, Effie W. Petersdorf, Ming-Tseh Lin, Steven Wang, Jason W. Chien, Barry Storer, Paul J. Martin. (2008) Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes. Immunologic Research 41:1, 56-78
CrossRef65
A H Elmaagacli, M Koldehoff, O Landt, D W Beelen. (2008) Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation. Bone Marrow Transplantation 41:9, 821-826
CrossRef66
Ove Schroeder, Klaus-Martin Schulte, Julia Schroeder, Axel Ekkernkamp, Reinhold Alexander Laun. (2008) The -1082 interleukin-10 polymorphism is associated with acute respiratory failure after major trauma: A prospective cohort study. Surgery 143:2, 233-242
CrossRef67
R. Zeiser, S. Youssef, J. Baker, N. Kambham, L. Steinman, R. S. Negrin. (2007) Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 110:13, 4588-4598
CrossRef68
Christian Erikstrup, Per Kallestrup, Rutendo B Zinyama-Gutsire, Exnevia Gomo, Anthony E Butterworth, Bente K Pedersen, Sisse R Ostrowski, Jan Gerstoft, Henrik Ullum. (2007) Reduced mortality and CD4 cell loss among carriers of the interleukin-10 −1082G allele in a Zimbabwean cohort of HIV-1-infected adults. AIDS 21:17, 2283-2291
CrossRef69
Raymond W. Redline. (2007) Villitis of unknown etiology: noninfectious chronic villitis in the placenta. Human Pathology 38:10, 1439-1446
CrossRef70
Yaping Sun, Isao Tawara, Tomomi Toubai, Pavan Reddy. (2007) Pathophysiology of acute graft-versus-host disease: recent advances. Translational Research 150:4, 197-214
CrossRef71
Mitsushige Sugimoto, Takahisa Furuta, Naohito Shirai, Akiko Nakamura, Masayoshi Kajimura, Haruhiko Sugimura, Akira Hishida. (2007) Effects of interleukin-10 gene polymorphism on the development of gastric cancer and peptic ulcer in Japanese subjects. Journal of Gastroenterology and Hepatology 22:9, 1443-1449
CrossRef72
Mari Malkki, Ted A. Gooley, Mary M. Horowitz, Lena Absi, Frank T. Christiansen, Jan J. Cornelissen, Anne Dormoy, Valerie Dubois, Katia Gagne, Eliane Gluckman, Michael D. Haagenson, Machteld Oudshoorn, Stephen Spellman, Effie W. Petersdorf. (2007) Mapping MHC-Resident Transplantation Determinants. Biology of Blood and Marrow Transplantation 13:8, 986-995
CrossRef73
Liang-Piu Koh, Chien-Shing Chen, Bee-Choo Tai, William Y.K. Hwang, Lip-Kun Tan, Hong-Yen Ng, Yeh-Ching Linn, Mickey B.C. Koh, Yeow-Tee Goh, Belinda Tan, Shan Lim, Yee-Mei Lee, Kar-Wai Tan, Te-Chih Liu, Heng-Joo Ng, Yvonne S.M. Loh, Benjamin M.F. Mow, Daryl C.L. Tan, Patrick H.C. Tan. (2007) Impact of Postgrafting Immunosuppressive Regimens on Nonrelapse Mortality and Survival after Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant Using the Fludarabine and Low-Dose Total-Body Irradiation 200-cGy. Biology of Blood and Marrow Transplantation 13:7, 790-805
CrossRef74
L L Warren, A R Hughes, E H Lai, D V Zaykin, S A Haneline, A T Bansal, A W Wooster, W R Spreen, J E Hernandez, T R Scott, A D Roses, M Mosteller. (2007) Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan. The Pharmacogenomics Journal 7:3, 180-189
CrossRef75
Anne M. Dickinson. (2007) Risk assessment in haematopoietic stem cell transplantation: Pre–transplant patient and donor factors: non-HLA genetics. Best Practice & Research Clinical Haematology 20:2, 189-207
CrossRef76
Kang-Hsi Wu, Ching-Tien Peng, Tsai-Chung Li, Lei Wan, Chang-Hai Tsai, Fuu-Jen Tsai. (2007) Interleukin-1?? Exon 5 and Interleukin-1 Receptor Antagonist in Children With Immune Thrombocytopenic Purpura. Journal of Pediatric Hematology/Oncology 29:5, 305-308
CrossRef77
E. Petersdorf, P. Bardy, A. Cambon-Thomsen, E. Goulmy, J. Hansen, A. Schwarer, A. Velardi, . (2007) 14th International HLA and Immunogenetics Workshop: Report on hematopoietic cell transplantation. Tissue Antigens 69, 17-24
CrossRef78
Lisbeth A. Welniak, Bruce R. Blazar, William J. Murphy. (2007) Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation. Annual Review of Immunology 25:1, 139-170
CrossRef79
Parinda A. Mehta, Mary Eapen, John P. Klein, Sharavi Gandham, James Elliott, Tiffany Zamzow, Michelle Combs, Richard Aplenc, Margaret L. MacMillan, Daniel J. Weisdorf, Effie Petersdorf, Stella M. Davies. (2007) Interleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia. British Journal of Haematology 137:2, 152-157
CrossRef80
Charles G. Mullighan, Peter G. Bardy. (2007) New Directions in the Genomics of Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 13:2, 127-144
CrossRef81
J N Wilson, K Rockett, B Keating, M Jallow, M Pinder, F Sisay-Joof, M Newport, D Kwiatkowski. (2006) A hallmark of balancing selection is present at the promoter region of interleukin 10. Genes and Immunity 7:8, 680-683
CrossRef82
F. E. Bertinetto, A. M. Dall?Omo, G. A. Mazzola, S. Rendine, M. Berrino, L. Bertola, P. Magistroni, P. Caropreso, M. Falda, F. Locatelli, A. Busca, A. Amoroso. (2006) Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation. International Journal of Immunogenetics 33:5, 375-384
CrossRef83
Maria Grazia Roncarolo, Silvia Gregori, Manuela Battaglia, Rosa Bacchetta, Katharina Fleischhauer, Megan K. Levings. (2006) Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans. Immunological Reviews 212:1, 28-50
CrossRef84
H T Greinix, G Socié, A Bacigalupo, E Holler, M G Edinger, J F Apperley, T Schwarz, S E Ullrich, M L Albert, R M Knobler, D Peritt, J L M Ferrara. (2006) Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplantation 38:4, 265-273
CrossRef85
Florence Bettens, Jakob Passweg, Alois Gratwohl, Yves Chalandon, Claudine Helg, Bernard Chapuis, Urs Schanz, Jolanta Libura, Eddy Roosnek, Jean-Marie Tiercy. (2006) Association of TNFd and IL-10 Polymorphisms with Mortality in Unrelated Hematopoietic Stem Cell Transplantation. Transplantation 81:9, 1261-1267
CrossRef86
Copelan, Edward A., . (2006) Hematopoietic Stem-Cell Transplantation. New England Journal of Medicine 354:17, 1813-1826
Full Text87
Manuela Battaglia, Silvia Gregori, Rosa Bacchetta, Maria-Grazia Roncarolo. (2006) Tr1 cells: From discovery to their clinical application. Seminars in Immunology 18:2, 120-127
CrossRef88
Daniel H. Fowler. (2006) Shared biology of GVHD and GVT effects: Potential methods of separation. Critical Reviews in Oncology/Hematology 57:3, 225-244
CrossRef89
L.-H. Tseng, M.-T. Lin, W.-Y. Shau, W.-C. Lin, F.-Y. Chang, K.-L. Chien, J. A. Hansen, D.-S. Chen, P.-J. Chen. (2006) Correlation of interleukin-10 gene haplotype with hepatocellular carcinoma in Taiwan. Tissue Antigens 67:2, 127-133
CrossRef90
Kirk R. Schultz, David B. Miklos, Daniel Fowler, Ken Cooke, Judith Shizuru, Emmanuel Zorn, Ernst Holler, James Ferrara, Howard Shulman, Stephanie J. Lee, Paul Martin, Alexandra H. Filipovich, Mary E.D. Flowers, Daniel Weisdorf, Daniel Couriel, Peter A. Lachenbruch, Barbara Mittleman, Georgia B. Vogelsang, Steven Z. Pavletic. (2006) Toward Biomarkers for Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. Biomarker Working Group Report. Biology of Blood and Marrow Transplantation 12:2, 126-137
CrossRef91
Effie W. Petersdorf, Mari Malkki. (2006) Genetics of Risk Factors for Graft-Versus-Host Disease. Seminars in Hematology 43:1, 11-23
CrossRef92
Søren L. Petersen, Hans O. Madsen, Lars P. Ryder, Arne Svejgaard, Ebbe Dickmeiss, Lars L. Vindeløv. (2006) Cytokine Gene Expression in Peripheral Blood Mononuclear Cells and Alloreactivity in Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning. Biology of Blood and Marrow Transplantation 12:1, 48-60
CrossRef93
H. Joachim Deeg, Joseph H. Antin. (2006) The Clinical Spectrum of Acute Graft-Versus-Host Disease. Seminars in Hematology 43:1, 24-31
CrossRef94
Vijay Reddy, Andrew G. Winer, Erika Eksioglu, Herwig-Ulf Meier-Kriesche, Jesse D. Schold, John R. Wingard. (2005) Interleukin 12 Is Associated with Reduced Relapse without Increased Incidence of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 11:12, 1014-1021
CrossRef95
N. Okayama, Y. Hamanaka, Y. Suehiro, Y. Hasui, J. Nakamura, Y. Hinoda. (2005) Association of Interleukin-10 Promoter Single Nucleotide Polymorphisms -819 T/C and -592 A/C With Aging. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:12, 1525-1529
CrossRef96
K W Seo, D H Kim, S K Sohn, N Y Lee, H H Chang, S W Kim, S B Jeon, J H Baek, J G Kim, J S Suh, K B Lee. (2005) Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplantation 36:12, 1089-1095
CrossRef97
Jeane Eliete Laguila Visentainer, Sofia Rocha Lieber, Lígia Beatriz Lopes Persoli, Sílvia Barbosa Dutra Marques, Afonso Celso Vigorito, Francisco José Penteado Aranha, Kátia Aparecida de Brito Eid, Gislaine Borba Oliveira, Eliana Cristina Martins Miranda, Luciana Bragotto, Cármino Antonio de Souza. (2005) Relationship between cytokine gene polymorphisms and graft-versus-host disease after allogeneic stem cell transplantation in a Brazilian population. Cytokine 32:3-4, 171-177
CrossRef98
Silvia Gregori, Rosa Bacchetta, Ehud Hauben, Manuela Battaglia, Maria-Grazia Roncarolo. (2005) Regulatory T cells: prospective for clinical application in hematopoietic stem cell transplantation. Current Opinion in Hematology 12:6, 451-456
CrossRef99
Anne M Dickinson, Dominique Charron. (2005) Non-HLA immunogenetics in hematopoietic stem cell transplantation. Current Opinion in Immunology 17:5, 517-525
CrossRef100
J N Wilson, K Rockett, M Jallow, M Pinder, F Sisay-Joof, M Newport, J Newton, D Kwiatkowski. (2005) Analysis of IL10 haplotypic associations with severe malaria. Genes and Immunity 6:6, 462-466
CrossRef101
Joseph P. Uberti, Lois Ayash, Voravit Ratanatharathorn, Samuel Silver, Christopher Reynolds, Michael Becker, Pavan Reddy, Kenneth R. Cooke, Gregory Yanik, Joel Whitfield, Dawn Jones, Raymond Hutchinson, Thomas Braun, James L.M. Ferrara, John E. Levine. (2005) Pilot Trial on the Use of Etanercept and Methylprednisolone as Primary Treatment for Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation 11:9, 680-687
CrossRef102
Masahiro Hirayama, Eiichi Azuma, Tadashi Kumamoto, Shotaro Iwamoto, Hiroshi Yamada, Yuji Nashida, Mariko Araki, Shinichi Kageyama, Shigehisa Tamaki, Keiki Kawakami, Hatsumi Yamamoto, Yoshihiro Komada. (2005) Prediction of Acute Graft-Versus-Host Disease and Detection of Distinct End-Organ Targets by Enumeration of Peripheral Blood Cytokine Spot-Forming Cells. Transplantation 80:1, 58-65
CrossRef103
M. Di Renzo, P. Rubegni, A.L. Pasqui, G. Pompella, G. De Aloe, P. Sbano, A. Cuccia, C. Castagnini, A. Auteri, F. Laghi Pasini, M. Fimiani. (2005) Extracorporeal photopheresis affects interleukin (IL)-10 and IL-12 production by monocytes in patients with chronic graft-versus-host disease. British Journal of Dermatology 153:1, 59-65
CrossRef104
Edward Gorak, Nancy Geller, Ramaprasad Srinivasan, Igor Espinoza-Delgado, Teresa Donohue, A. John Barrett, Anthony Suffredini, Richard Childs. (2005) Engraftment Syndrome after Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Effects on Survival. Biology of Blood and Marrow Transplantation 11:7, 542-550
CrossRef105
Dong Hwan Kim, Nan Young Lee, Sang Kyun Sohn, Jin Ho Baek, Jong Gwang Kim, Jang Soo Suh, Kyu Bo Lee, Im Hee Shin. (2005) IL-10 Promoter Gene Polymorphism Associated with the Occurrence of Chronic GVHD and Its Clinical Course During Systemic Immunosuppressive Treatment for Chronic GVHD after Allogeneic Peripheral Blood Stem Cell Transplantation. Transplantation 79:11, 1615-1622
CrossRef106
Lidia Karabon, Barbara Wysoczanska, Katarzyna Bogunia-Kubik, Krzysztof Suchnicki, Andrzej Lange. (2005) IL-6 and IL-10 Promoter Gene Polymorphisms of Patients and Donors of Allogeneic Sibling Hematopoietic Stem Cell Transplants Associate With the Risk of Acute Graft-Versus-Host Disease. Human Immunology 66:6, 700-709
CrossRef107
Gaelle Gillerot, Eric Goffin, Catherine Michel, Pieter Evenepoel, Wim Van Biesen, Michel Tintillier, Peter Stenvinkel, Olof Heimburger, Bengt Lindholm, Louise Nordfors, Annie Robert, Olivier Devuyst. (2005) Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney International 67:6, 2477-2487
CrossRef108
X P Ju, B Xu, Z P Xiao, J Y Li, L Chen, S Q Lu, Z X Huang. (2005) Cytokine expression during acute graft-versus-host disease after allogeneic peripheral stem cell transplantation. Bone Marrow Transplantation 35:12, 1179-1186
CrossRef109
Annette H. M van der Helm-van Mil, Joanna Z Wesoly, Tom W. J Huizinga. (2005) Understanding the genetic contribution to rheumatoid arthritis. Current Opinion in Rheumatology 17:3, 299-304
CrossRef110
J-H Lee, S-J Choi, J-H Lee, Y-S Lee, M Seol, S-G Ryu, J-S Lee, W-K Kim, K-H Lee. (2005) Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplantation 35:8, 755-761
CrossRef111
Eskandar Kamali-Sarvestani, Jale Zolghadri, Behrouz Gharesi-Fard, Jamal Sarvari. (2005) Cytokine gene polymorphisms and susceptibility to recurrent pregnancy loss in Iranian women. Journal of Reproductive Immunology 65:2, 171-178
CrossRef112
Marco Mielcarek, Theodore Gooley, Paul J. Martin, Thomas R. Chauncey, Bessie A. Young, Rainer Storb, Beverly Torok-Storb. (2005) Effects of race on survival after stem cell transplantation. Biology of Blood and Marrow Transplantation 11:3, 231-239
CrossRef113
Uwe Langsenlehner, Peter Krippl, Wilfried Renner, Babak Yazdani-Biuki, Tanja Eder, Herwig K
ppel, Thomas C. Wascher, Bernhard Paulweber, Hellmut Samonigg. (2005) Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Research and Treatment 90:2, 113-115
CrossRef114
Dana C. Crawford, Deborah A. Nickerson. (2005) Definition and Clinical Importance of Haplotypes. Annual Review of Medicine 56:1, 303-320
CrossRef115
John A. Hansen. (2005) T-cell alloreactivity in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 11:2, 24-27
CrossRef116
Javier Bola??os-Meade, Georgia B Vogelsang. (2005) Novel strategies for steroid-refractory acute graft-versus-host disease. Current Opinion in Hematology 12:1, 40-44
CrossRef117
Bertrand L. Jaber, Brian J.G. Pereira, Joseph V. Bonventre, Vaidyanathapuram S. Balakrishnan. (2005) Polymorphism of host response genes: Implications in the pathogenesis and treatment of acute renal failure. Kidney International 67:1, 14-33
CrossRef118
Marco Mielcarek, Rainer Storb. (2005) Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leukemia & Lymphoma 46:9, 1251-1260
CrossRef119
Anne M. Dickinson, Peter G. Middleton, Vanderson Rocha, Eliane Gluckman, Ernst Holler, . (2004) Genetic polymorphisms predicting the outcome of bone marrow transplants. British Journal of Haematology 127:5, 479-490
CrossRef120
Marcel P. Devetten, Julie M. Vose. (2004) Graft-versus-host disease: How to translate new insights into new therapeutic strategies. Biology of Blood and Marrow Transplantation 10:12, 815-825
CrossRef121
Gerhard Rogler, Ernst Holler. (2004) Can NOD2/CARD15 mutations predict intestinal graft-versus-host disease and aid our understanding of Crohn's disease?. Nature Clinical Practice Gastroenterology & Hepatology 1:2, 62-63
CrossRef122
Nigel C. K. Tan, John C. Mulley, Samuel F. Berkovic. (2004) Genetic Association Studies in Epilepsy: "The Truth Is Out There". Epilepsia 45:11, 1429-1442
CrossRef123
Charles G. Mullighan, Peter G. Bardy. (2004) Advances in the genomics of allogeneic haemopoietic stem cell transplantation. Drug Development Research 62:3, 273-292
CrossRef124
Tetsuya E. Tanimoto, Takuhiro Yamaguchi, Yuji Tanaka, Akiko Saito, Kinuko Tajima, Takahiro Karasuno, Masanobu Kasai, Kenji Kishi, Takehiko Mori, Nobuo Maseki, Satoko Morishima, Shigesaburo Miyakoshi, Masaharu Kasai, Yuju Ohno, Sung-Won Kim, Akihiko Numata, Masahiro Kami, Yoichi Takaue, Shin-ichiro Mori, Mine Harada. (2004) Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. British Journal of Haematology 125:4, 480-493
CrossRef125
(2004) Interleukin-10 and Graft-versus-Host Disease. New England Journal of Medicine 350:13, 1361-1362
Full Text126
Ian S Gourley, David Denofrio, William Rand, Shashank Desai, Evan Loh, Malek Kamoun. (2004) The effect of recipient cytokine gene polymorphism on cardiac transplantation outcome. Human Immunology 65:3, 248-254
CrossRef127
Hans-Jochem Kolb, Belinda Simoes, Christoph Schmid. (2004) Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies. Current Opinion in Oncology 16:2, 167-173
CrossRef128
Cooke, Kenneth R., Ferrara, James L.M., . (2003) A Protective Gene for Graft-versus-Host Disease. New England Journal of Medicine 349:23, 2183-2184
Full Text
- Letters
